Cancer Cover in Critical Illness Insurance: Definitions, Partial Payments, and Gaps

Cancer is by far the most common critical illness claim. Approximately one in two people in the UK will be diagnosed with cancer at some point in their lifetime, and for women particularly — where breast cancer is the most commonly diagnosed cancer — the probability of a cancer critical illness claim over a working lifetime is substantial. For HNW clients who have invested in critical illness cover, understanding exactly what is and is not covered is not a technicality: it determines whether a policy pays in the moment it matters most.

Critical illness cancer definitions are more nuanced than many policyholders realise. Not all cancers are covered. Some cancers pay a partial benefit rather than the full sum assured. The survival period matters. And for internationally mobile clients, the cost of private cancer treatment can run to hundreds of thousands of pounds. This guide explains the framework.

The ABI Model Definition for Cancer

The Association of British Insurers (ABI) publishes model minimum definitions for critical illness claims, including cancer. The current ABI definition requires:

"A malignant tumour characterised by the uncontrolled growth and spread of malignant cells with invasion and destruction of normal tissue. This diagnosis must be supported by histological evidence of malignancy."

The definition then specifies a list of exclusions — cancer types that do not qualify for payment under the standard definition. Understanding these exclusions is essential.

What Is Excluded: Carcinoma In Situ

The most significant exclusion for many policyholders is carcinoma in situ — cancerous cells confined to their site of origin that have not invaded surrounding tissue. Carcinoma in situ is a pre-invasive lesion: it may develop into invasive cancer, or it may not.

Common examples of excluded carcinoma in situ:

• CIN 1, 2, or 3 (Cervical Intraepithelial Neoplasia) — The cervical screening programme specifically detects CIN. Grade 3 (the most severe) represents a significant abnormality but is still excluded from standard critical illness definitions.
• Ductal carcinoma in situ (DCIS) of the breast — The most common form of non-invasive breast cancer, affecting around 7,000 women per year in the UK. Despite often requiring mastectomy, DCIS does not qualify under the standard cancer CI definition.
• Bladder tumours that are non-invasive (Ta)
• Melanoma in situ

For women, the exclusion of DCIS is particularly significant. A woman who is diagnosed with DCIS and undergoes mastectomy may expect to claim on her critical illness policy. Under a standard policy, the claim is declined.

Some insurers offer an enhanced definition or an additional DCIS payment benefit that provides a partial payment for DCIS — typically 25% of the sum assured. This is a meaningful product differentiator worth investigating when selecting a CI policy.

Other Excluded Cancer Types

Beyond carcinoma in situ, standard CI policies exclude certain cancers based on stage or type:

Early-stage prostate cancer: Many policies exclude prostate cancer with a Gleason score of 6 or below, confined to the prostate (T1 or T2 staging). Higher Gleason scores and locally advanced or metastatic disease are covered.

Early-stage thyroid cancer (T1 with no nodal involvement): Similarly excluded by some insurers on the basis that the prognosis for early-stage thyroid cancer is excellent.

Non-melanoma skin cancers: Basal cell carcinoma and squamous cell carcinoma of the skin are commonly excluded from the main cancer benefit. These are usually localised, highly treatable, and do not require the same level of intervention as other cancers.

The precise definitions and exclusions vary between insurers. A policy from one insurer may cover early prostate cancer where another explicitly excludes it. These differences are not always prominent in marketing materials, making it essential to read the full policy wording or ask an adviser to compare definitions directly.

Full Payment versus Partial Payment Cancer Definitions

A growing feature of comprehensive critical illness policies is the distinction between full payment and partial payment for different cancer stages and types.

Full payment: The full sum assured is paid for invasive cancers meeting the standard ABI-aligned definition — malignant, histologically confirmed, non-excluded. If the sum assured is £300,000, the full £300,000 is paid.

Partial payment (also called additional or supplementary payment): Some insurers pay a lower amount — typically 25% of the sum assured, capped at £25,000 or £50,000 depending on the insurer — for:

• DCIS of the breast
• Certain early-stage prostate cancers
• Carcinoma in situ of specified sites
• Melanoma in situ

The partial payment is designed to acknowledge the diagnosis and provide some financial relief, even where the full CI definition is not met. It does not deplete the full sum assured — a subsequent claim for a full-payment cancer would still pay the complete benefit.

Not all insurers offer partial payment for any cancer type. When comparing CI policies, specifically ask which cancers attract partial payment and what the cap is.

The Survival Period

Most critical illness policies require the insured to survive for a specified period after diagnosis before the claim is paid. The standard survival period is 14 days, though some policies use 28 days.

The purpose of the survival period is to prevent insurers from paying claims where the condition diagnosed is so severe that the insured dies within days — the CI policy's intent is to support living with a serious illness, not to duplicate a life policy's death benefit. For terminal cancer diagnoses, the terminal illness benefit on a life policy may be more appropriate.

For most cancer diagnoses — where treatment and recovery over months or years is the expected trajectory — the 14-day survival period is rarely problematic in practice. The policy pays once the claimant has survived the waiting period and the claim is agreed.

However, for aggressive cancers where prognosis is poor at diagnosis, the survival period can occasionally create a claim window problem. Clients with life assurance and critical illness should check whether their life policy's terminal illness benefit (typically available where life expectancy is less than 12 months) activates earlier and provides equivalent financial relief.

Cancer Recurrence: A Critical Policy Gap

One of the most important limitations of standard critical illness policies is the treatment of cancer recurrence. Standard CI policies pay once on a cancer claim and do not pay a second time for a recurrence of the same cancer.

Consider a woman who is diagnosed with invasive breast cancer at age 42, claims the full sum assured on her CI policy, and recovers following treatment. Twelve years later, the cancer recurs. Her CI policy has been paid out and is exhausted — there is no second claim, even though the recurrence may be as financially and medically serious as the original diagnosis.

Some insurers offer a limited recurrence benefit — a second payment, typically a percentage of the original sum, on recurrence after a specified disease-free interval (commonly five to seven years). This is not standard and is available from only a minority of providers.

The absence of recurrence cover is a specific gap that clients who have already made a cancer claim should be aware of. New cover for a cancer survivor is difficult to obtain (exclusions apply), making the recurrence benefit on the original policy particularly valuable.

Cancer Treatment Costs for International Clients

For clients who live or work internationally, or who wish to access world-leading private cancer treatment in the UK, treatment costs can be substantial.

Private cancer treatment in the UK ranges widely depending on the cancer type, treatment modality, and the centre of excellence used. Indicative private treatment costs in 2026:

• Breast cancer (surgery, chemotherapy, radiotherapy): £40,000–£120,000 depending on staging and reconstruction
• Prostate cancer (radical prostatectomy or radiotherapy): £20,000–£50,000
• Bowel cancer (surgery and chemotherapy): £50,000–£100,000
• Complex cancers (lymphoma, leukaemia, multiple myeloma) requiring bone marrow transplant or novel therapies: £100,000–£300,000+

Novel immunotherapy treatments — particularly CAR-T cell therapy for certain blood cancers — can cost £350,000–£400,000 per course of treatment. NHS access to these therapies is available through NICE-approved pathways, but private access accelerates the timeline significantly for private patients.

For internationally based clients seeking treatment in the UK, costs also include accommodation, travel, and supporting family members during extended treatment stays. A CI lump sum that adequately addresses these costs — not just the direct medical bill — requires careful sizing.

Private medical insurance (PMI) covers ongoing cancer treatment costs on an expense-reimbursement basis for most standard treatment protocols, but PMI typically has annual limits and may have gaps in coverage for experimental treatments, recurrence, or very long-term management. CI cover provides a capital lump sum that can supplement PMI, cover gaps, and fund non-medical financial consequences of diagnosis.

Children's Critical Illness Cover

Most comprehensive CI policies include children's critical illness cover within the family policy at no additional premium. Key features of children's CI benefit:

• Typically covers children from 30 days old (or from birth for some conditions) up to age 18 or 21
• Coverage typically includes paediatric conditions — children's cancers, meningitis, total permanent disability, and certain children-specific conditions
• Benefit is often capped — commonly 25% of the parent's sum assured, subject to an overall cap (e.g. £25,000)
• Does not exhaust the parent's sum assured — a children's claim is an additional benefit, not paid from the main benefit

For parents, the financial consequences of a child's serious illness include time away from work (impacting the parent's income), travel and accommodation costs during treatment, adaptations to the home, and the psychological impact on the family. Children's CI provides a capital sum to help meet these costs.

When comparing CI policies with families in mind, check:

• Age range covered
• Conditions included (some policies have a more comprehensive paediatric list than others)
• Whether the children's benefit is separate from or part of the main sum assured

How to Choose the Right CI Cancer Cover

Given the variations in cancer coverage between insurers, the selection criteria for a CI policy with strong cancer cover should include:

1. Full ABI-aligned invasive cancer definition — baseline requirement
2. Partial payment for DCIS — specifically for female clients
3. Coverage of early-stage prostate cancer — relevant for male clients
4. Recurrence benefit — ideally with a five-year disease-free interval
5. Survival period of 14 days (not 28) — marginally better for aggressive diagnoses
6. Comprehensive children's CI — for parents

An independent protection adviser can compare the specific cancer definitions across a broad panel of insurers and identify which policy best matches the client's priorities. Generic premium comparisons miss the definition quality differences that determine whether a claim is paid.

How Global Investments Can Help

Global Investments provides detailed critical illness policy analysis for HNW clients and their families. We compare cancer definitions across insurers, highlight specific inclusion and exclusion differences that matter for your demographic, and advise on appropriate sum assured levels given your treatment cost expectations and private medical insurance arrangements.

For internationally based clients who rely on London private hospitals for specialist treatment, we ensure that CI sum assured levels are calibrated to actual treatment costs, not generic benchmarks. Contact us to review your existing critical illness cover or to arrange a new policy.

This guide is for information only and does not constitute regulated financial advice. Cancer diagnoses and CI claim eligibility depend on individual medical circumstances and specific policy terms. Seek independent professional advice before making protection decisions. Cancer statistics sourced from Cancer Research UK (2025).